NRX Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 14, 2024 and accepted by EDGAR at Nov 14, 2024, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 9 months2024-01-01 to 2024-09-30 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $611.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $5.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$3.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$16.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-07-01 to 2024-09-30 | $0 | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2024-01-01 to 2024-09-30 | $230.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$16.0m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$1.59 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$8.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $0 | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-09-30 | $1.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $4.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $4.5m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $20.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $23.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | −$18.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-035289. Last ingested by Listed: Nov 2, 2026, 08:07 ET. Listed shows no prices and gives no investment advice.